Scientists from the National Surgical Adjuvant Breast and Bowel Project (NSABP) who conducted the landmark Breast Cancer Prevention Trial (BCPT), report a seven-year and final update of the trial results in the November 16, 2005, Journal of the National Cancer Institute*. In this final report, reductions in breast cancer incidence among participants taking tamoxifen were found to be very similar compared to those reported in 1998 when initial findings from the BCPT were released. The conclusion is supported by the observation that the incidence rate of breast cancer was relatively constant through seven years of follow-up among women who received tamoxifen and by the fact that the rate remained stable for at least two years beyond the time that women stopped taking the drug. The risks of stroke, deep-vein thrombosis, and cataracts -- possible side-effects of tamoxifen treatment -- were also similar to those reported previously. ......


Click Here to read the entire article...